期刊文献+

小肠间质瘤致消化道出血一例

原文传递
导出
摘要 患者男,57岁.因黑便4d,于2013年3月12日入院.该患于入院前4d出现黑便,为柏油样,共4次.第1次黑便后出现晕厥,未应用药物治疗患者自行苏醒,后头晕、乏力明显,伴口渴,伴上腹痛,疼痛性质为烧灼痛,以饥饿痛为主,进餐后可略缓解,疼痛无放散,伴腹胀.入院查体:体温:36.5℃脉搏:80次/min,呼吸:17次/min,血压:105/50mmHg(1 mmHg=0.133 kPa),一般状态差,贫血貌,神志清楚,查体合作,上腹部轻压痛,未触及腹部包块,余查体无阳性体征.血常规:红细胞计数:2.27×1012/L;血红蛋白含量:77 g/L;红细胞压积:21.5%.胃镜示:食管黏膜光滑,近贲门见一3 mm×3 mm黄色斑,管腔通畅,蠕动良好.贲门黏膜充血、水肿,开放与关闭良好.胃体黏膜光滑、色泽正常,蠕动良好,粘液湖淡黄色,液体量中等.
出处 《中国综合临床》 2014年第3期334-334,共1页 Clinical Medicine of China
基金 吉林省自然科学基金项目(201115083)
  • 相关文献

参考文献4

  • 1Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis [ J ]. Am J Surg Pathol, 1983,7 (6) :507-519.
  • 2Ogasawara N, Tsukamoto T, Inada K, et al. Frequent c-Kit gene mutations not only in gastrointestinal stromal tumors but also in interstitial cells of Cajal in surrounding normal mucosa [ J ]. Cancer Lett ,2005,230(2) :199-210.
  • 3Jass J R. Tumors of the small and large intestines ( including the anal region ) In: Fletcher CDM, ed, Diagnostic histopathology of tumors [M]. 3rd ed, Philadelphia, Pa: Churchill Livingstone Elsevier, 2007 : 381-383.
  • 4高伟,薛春燕,王雅杰.甲磺酸伊马替尼治疗复发或转移胃肠间质瘤35例[J].中国综合临床,2012,28(5):517-519. 被引量:2

二级参考文献14

  • 1Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors [J]. Ann Surg Oncol,2007,14 ( 1 ) : 134-142.
  • 2Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up [ J]. Ann Oncol,2009, Suppl 4:64-67.
  • 3Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1 ) [J]. Eur J Cancer,2009,45(2) :228-247.
  • 4National Institutes of Health. Common Terminology Criteria for Adverse Events Verson 3.0 [EB/OL].2003 [ 2011-11-10]. http ://etep. cancer, gov/protocolDevelopment/electronic_ applications/ctc, htm.
  • 5DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival [ J]. Ann Surg,2000,231 (1) :51-58.
  • 6Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c - kit in human gastrointestinal stromal tumors [ J ]. Science, 1998,279 (5350) :577-580.
  • 7Verweij J, Casali PG, Zalcberg J, et al. Progression- free survival in gastrointestinal stromal tumours with high - dose imatinib: randomised trial [ J ]. Lancet,2004,364 ( 9440 ) : 1127-1134.
  • 8Zalcberg JR,Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg [J]. Eur J Cancer,41 (12) :1751-1757.
  • 9Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors : a meta- analysis of 1,640 patients [ J]. J Clin Oncol,2010,28 (7) :1247- 1253.
  • 10Demetri GD,van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial [ J ]. Lancet, 2006,368 ( 9544 ) : 1329 -1338.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部